Multi-center, Randomized, Vehicle-controlled, Investigator-blinded, Parallel Groups Study to Evaluate the Efficacy and Safety of NP000888 in Subjects With Plaque and Nail Psoriasis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs NP 000888 (Primary)
- Indications Plaque psoriasis; Psoriasis
- Focus Therapeutic Use
- Sponsors Galderma
- 21 Nov 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 21 Nov 2017 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.